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"I AM ALREADY involved in for-
mulating standards for American 
and European companies engaged 
in genetic engineering of crops 
and I am very agreeable to the 
idea of drawing up norms for 
companies involved in commer-
cialising technology derived from 
the biodiversity of Third World 
countries, in sectors like medici-
nal plants," says Dr Peter Raven', 
member of President Clinton's ad-
visory committee on science and 
technology. He is also chairman 
of the report review committee of 
the National Research Council. 
I «.Dr Raven told The Economic 
, Times that some of the norms for 
genetic engineering were manda-
; tory (like those concerning re-
, lease of organisms and testing be-
fore planting) and some voluntary. 
' Replying to a query, he agreed that 
i much of the suspicion in Third 
World countries regarding the 
commercialisation by multina-
oitionals of their biodiversity could 
"be removed if there were norms 
wtfor American and European com-
nspanies engaged in this sector. 
At present, there were no over-
' all norms drawn up for American 
r. and European companies seeking 
•4o commercialise technology de-
' 'rived from Third World biodiversi-
•ity. Whatever norms were there 
^iwere formulated by individual 
..Third World countries. For in-
ni'stance, Costa Rica had a National 
"[''Institute of Biodiversity. Any for-
eign company seeking to com-
mercially exploit the biodiversdity 
of Costa Rica had to not only pay 
a sum up front (to be utilised for 
the benefit of the local people in 
the area) but also had to sign an 
agreement agreeing to pay the in-
stitute 50 per cent of the royalties 
derived from any patent. The key 
issue was not so much the patent 
but the licensing of applications, 
Dr Raven said. 
In the case of India, there was 
no kind of framework in place and 
hence there was a fair amount of 
confusion and controversy, some 
of it politically generated, he felt. 
In a world which was growing 
progressively smaller with techno-
logical upgradation, multination-
als would themselves be all for a 
system with transparency, he 
said. 
• Asked about Ricetec's patent-
ing of Basmati in the US, he said, 
"I do not have all the details but, if 
they have patented something 
which is widely grown in India, 
then, on the face of things, it 
would seem ridiculous. However, 
I do not agree that the US Patent 
Office rushes things through. It 
takes sometimes a year for the of-
fice to agree to process an applica-
tion and then the actual process 
takes some more years." 
Earlier, at an international con-
ference on medicinal plants, Dr 
Vandana Shiva lambasted the 
multinationals for, as she put it, 
trying to patent life forms which 
belonged to Third World biodiver-
sity. It was, she said, all indicative 
of an acquisitive culture which 
sought to monopolise something 
engrained in traditional systems 
of medicine over the ages. She 
characterised the process as one 
where Third World biodiversity 
became the raw material for 
patents for MNCs which used 
their clout to have this rammed 
down the throats of the South in 
the form of intellectual property 
rights ratified by the World Trade 
Agreement. 
Dr Gerard Bodeker of the Insti-
tute of Health Sciences, University 
of Oxford, cited instances where 
the discovery of the efficacy of a 
medicinal plant had resulted in its 
over-exploitation to an extent 
where it had almost become inac-
cessible to the common people 
who had been using it for ages. In-
stead, the plant had now become a 
complementary medicine for the 
elite in Addis Ababa as also in the 
West! 
Presenting some of the findings 
of the programme to formulate a 
People's Biodiversity Register 
(carried out in selected villages in 
seven states over the last two 
years or so), Dr Madhav Gadgil 
said that some of the richest biodi- • 
versity was found in the poorest 
areas and that those most aware 
of the potential were often those 
tb benefit the least from it. He cit-
ed the instance of a village in the 
Western Ghats near Pune. 
Dr Andrew Cunningham, re-
gional co-ordinator (Africa), 
WWF/Unesco/Kew People & 
Plants' Initiative, estimated global 
trade in medicinal plants at 
around $800 million a year. The 
export trade was, he said, domi-
nated by China (1,21,000 tonnes! a 
year) followed by India wilh 
32,600 tonnes. | 
